Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib

<p>Abstract</p> <p>Background</p> <p>Tyrosine kinase inhibitors (TKIs) are currently approved for the treatment of metastatic renal cell carcinoma (mRCC). The cardiotoxic effects of sorafenib and sunitinib may cause hypertension, left ventricular ejection fraction (LVEF...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Pantaleo Maria, Mandrioli Anna, Saponara Maristella, Nannini Margherita, Erente Giovanna, Lolli Cristian, Biasco Guido
Format: Artigo
Jezik:Inglês
Izdano: BMC 2012-06-01
Serija:BMC Cancer
Teme:
Sorafenib
renal cell carcinoma
coronary syndrome
cardiotoxicity
cardiac ischemia/infarction
Online dostop:http://www.biomedcentral.com/1471-2407/12/231
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki